【摘要】 目的　探讨急性髓性白血病 (AML)体内、外联合化疗方案的敏感性及药物间的相互关系 ,为临床治疗提供最有效的化疗方案。方法　采用MTT体外药敏法 ,利用倍增模型分析法和最大限度模型分析法研究体外化疗药物间的相互作用关系及对白血病细胞的敏感性 ,并观察体内、外药物敏感性的关系。结果　在 5 7例AML中体外对HA方案敏感 35例 (6 1% ) ,对DA方案敏感 33例 (5 8% ) ,对MA方案敏感 33例 (5 8% ) ;HA协同或相加作用占 72 % ;DA协同或相加作用占 74 % ;MA协同或相加作用占 74 % ;经临床治疗有结果可判断疗效的共同 39例 ,S/S19例 ,S/R6例 ,R/R11例 ,R/S3例 (S :敏感 ,R :耐药 ,体内 /体外 ) ,体内、外总符合率 76 .9%。结论　联合化疗方案HA、DA、MA是治疗AML患者的有效方案 ,化疗药物间大多数是起相互协同作用或相加用用 ,少数为拮抗作用 ,通过体外药物敏感试验发现三种常用化疗方案相互作用起协同或相加作用占 70 %以上 ,与临床缓解率相近 ,故选择敏感化疗方案是提高缓解率的有效办法。更多还原

【Abstract】 Objective To explore the sensitivity of combined chemotherapy regimens for AML in vivo and in vitro.Methods The effect of chemotherapeutic drugs in AML cells was investigated by MTT assay,“multiplicative” model and the ”maximum” model analysis method.Results (1).Thirty-five of fifty-seven (61%) patients were sensitive to HA,33(58%) sensitive to DA,33(58%)sensitive to MA.(2).synergism and antagonism was 72% between HHT and Ara-c,74% between DNR and Ara-c,74%between MTZ and Ara-c.There were 39 patients were judged the clinical effect,S/S 19 cases,S/R 6 case ,R/R 11cases,R/S 3 cases(S:sensitivity,R:resistance,in vitro/in vivo).The general coincident rate of in vitro and in vivo was 76.9%.Conclusion The combined chemotherapy regimens such as HA、DA and MA would be effective regimens for AML patients.There is synergism or additive among most of chemotherapy regimens,which is similar to the rate of clinical remission.更多还原